Please login to the form below

Not currently logged in
Email:
Password:

CAR T therapy

This page shows the latest CAR T therapy news and features for those working in and with pharma, biotech and healthcare.

Kite’s CAR-T therapy Yescarta shows positive results in second-line lymphoma study

Kite’s CAR-T therapy Yescarta shows positive results in second-line lymphoma study

Gilead company Kite has unveiled positive results for its CAR-T therapy Yescarta in the second-line setting for relapsed or refractory large B-cell lymphoma (LBCL).  . ... The CAR-T therapy also met key secondary endpoints of complete response rate and

Latest news

More from news
Approximately 19 fully matching, plus 97 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 1 fully matching, plus 25 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

  • In the precision medicine era, the line between products and services is blurred

    In a nutshell, CAR-T therapy involves extracting T-cells (a type of white blood cells that play a key role in immune response) from the patient, genetically engineering them to ... However, due to its novelty, it was difficult to access patients who have

  • The impossible launch

    SpaceX is inspiring people in a way that NASA hasn’t managed in over 30 years. ... Today’s therapy advances, such as CAR-T and gene therapy, are just as exciting and will help shape our world in the years to come.

  • Understanding the evolving CAR-T market

    In August 2017, Novartis made history after receiving FDA approval for Kymriah, the world’s first chimeric antigen receptor T-cell (CAR-T) therapy. ... Today, the CAR-T market is expected to increase at an annual rate of 30% until 2030.

  • Precision paediatrics: Treating patients with CAR-T

    Here, we discuss the story behind CAR-T therapy and the steps being taken to ensure more patients can access it. ... It’s an exciting time for CAR-T therapy. SA: It’s an integrated, holistic approach.

  • Highlights in haematologic malignancy from ASH 2018

    The spotlight shone on Chimeric Antigen Receptor(CAR) T-cell therapy; a transformative approach where the patient’s T cells are harvested and re-engineered to recognise antigens expressed by the ... A reduced risk of relapse was also seen when

More from PMHub
Approximately 0 fully matching, plus 8 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Mednet Group

Communique Small consultancy of the year 2020. With diversity and inclusion at our core, Mednet Group consists of Attigo CIC...

Latest intelligence

JulAug cover image
The Chronicles of Pharma: a creative review of pharma’s journey to omnichannel
Chris Ross conducts a literary-inspired review of pharma’s pursuit of communications excellence...
The key to psoriasis innovation? Dispelling the shadow of the JAK inhibitor
Powerful therapies that can improve skin clarity dominate the psoriasis landscape, so why are most patients stuck in a cycle of ineffective topicals? Fishawack Health explores the market and reveals...
Virtual Speaker Program: A Customer Story
Learn how we helped our client develop a virtual speaker program and roll out a series of regional peer-to-peer education sessions....